Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow …
M Mohty, F Malard, M Abecassis, E Aerts… - Bone marrow …, 2015 - nature.com
Sinusoidal obstruction syndrome or veno-occlusive disease (SOS/VOD) is a potentially life-
threatening complication of hematopoietic SCT (HSCT). This review aims to highlight, on …
threatening complication of hematopoietic SCT (HSCT). This review aims to highlight, on …
Distant organ dysfunction in acute kidney injury: a review
Acute kidney injury (AKI) is common in critically ill patients and is associated with increased
morbidity and mortality. Dysfunction of other organs is an important cause of poor outcomes …
morbidity and mortality. Dysfunction of other organs is an important cause of poor outcomes …
Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for …
S Corbacioglu, E Carreras, M Ansari… - Bone marrow …, 2018 - nature.com
The advances in hematopoietic cell transplantation (HCT) over the last decade have led to a
transplant-related mortality below 15%. Hepatic sinusoidal obstruction syndrome/veno …
transplant-related mortality below 15%. Hepatic sinusoidal obstruction syndrome/veno …
Pathophysiology of GvHD and other HSCT-related major complications
S Ghimire, D Weber, E Mavin, XN Wang… - Frontiers in …, 2017 - frontiersin.org
For over 60 years, hematopoietic stem cell transplantation has been the major curative
therapy for several hematological and genetic disorders, but its efficacy is limited by the …
therapy for several hematological and genetic disorders, but its efficacy is limited by the …
[HTML][HTML] Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment
Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome
(SOS), can develop in a subset of patients, primarily after myeloablative hematopoietic stem …
(SOS), can develop in a subset of patients, primarily after myeloablative hematopoietic stem …
[HTML][HTML] Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome
S Corbacioglu, EJ Jabbour, M Mohty - Biology of Blood and Marrow …, 2019 - Elsevier
Veno-occlusive disease, also known as sinusoidal obstruction syndrome (VOD/SOS), is a
potentially life-threatening complication of allogeneic or autologous hematopoietic stem cell …
potentially life-threatening complication of allogeneic or autologous hematopoietic stem cell …
Diagnosis and treatment of VOD/SOS after allogeneic hematopoietic stem cell transplantation
F Bonifazi, F Barbato, F Ravaioli, M Sessa… - Frontiers in …, 2020 - frontiersin.org
Hepatic veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS) is a rare
complication characterized by hepatomegaly, right-upper quadrant pain, jaundice, and …
complication characterized by hepatomegaly, right-upper quadrant pain, jaundice, and …
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society …
M Mohty, F Malard, M Abecassis, E Aerts… - Bone marrow …, 2016 - nature.com
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a
potentially life threatening complication that can develop after hematopoietic cell …
potentially life threatening complication that can develop after hematopoietic cell …
Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for …
M Mohty, F Malard, AS Alaskar, M Aljurf… - Bone marrow …, 2023 - nature.com
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a
potentially life-threatening complication that can develop after hematopoietic cell …
potentially life-threatening complication that can develop after hematopoietic cell …
Management of important adverse events associated with inotuzumab ozogamicin: expert panel review
Inotuzumab ozogamicin (InO), a humanized anti-CD22 monoclonal antibody conjugated to
the cytotoxic antibiotic agent calicheamicin, has demonstrated efficacy in the phase 3 INO …
the cytotoxic antibiotic agent calicheamicin, has demonstrated efficacy in the phase 3 INO …